Ferrari, S.M.; Ragusa, F.; Elia, G.; Mazzi, V.; Balestri, E.; Botrini, C.; Rugani, L.; Patrizio, A.; Piaggi, S.; La Motta, C.;
et al. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. Int. J. Mol. Sci. 2024, 25, 6734.
https://doi.org/10.3390/ijms25126734
AMA Style
Ferrari SM, Ragusa F, Elia G, Mazzi V, Balestri E, Botrini C, Rugani L, Patrizio A, Piaggi S, La Motta C,
et al. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. International Journal of Molecular Sciences. 2024; 25(12):6734.
https://doi.org/10.3390/ijms25126734
Chicago/Turabian Style
Ferrari, Silvia Martina, Francesca Ragusa, Giusy Elia, Valeria Mazzi, Eugenia Balestri, Chiara Botrini, Licia Rugani, Armando Patrizio, Simona Piaggi, Concettina La Motta,
and et al. 2024. "Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro" International Journal of Molecular Sciences 25, no. 12: 6734.
https://doi.org/10.3390/ijms25126734
APA Style
Ferrari, S. M., Ragusa, F., Elia, G., Mazzi, V., Balestri, E., Botrini, C., Rugani, L., Patrizio, A., Piaggi, S., La Motta, C., Ulisse, S., Virili, C., Antonelli, A., & Fallahi, P.
(2024). Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro. International Journal of Molecular Sciences, 25(12), 6734.
https://doi.org/10.3390/ijms25126734
